Cargando…
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/ https://www.ncbi.nlm.nih.gov/pubmed/28862704 http://dx.doi.org/10.1038/leu.2017.247 |
| _version_ | 1783275683246505984 |
|---|---|
| author | Hughes, T P Leber, B Cervantes, F Spector, N Pasquini, R Clementino, N C D Schwarer, A P Dorlhiac-Llacer, P E Mahon, F-X Rea, D Guerci-Bresler, A Kamel-Reid, S Bendit, I Acharya, S Glynos, T Dalal, D Branford, S Lipton, J H |
| author_facet | Hughes, T P Leber, B Cervantes, F Spector, N Pasquini, R Clementino, N C D Schwarer, A P Dorlhiac-Llacer, P E Mahon, F-X Rea, D Guerci-Bresler, A Kamel-Reid, S Bendit, I Acharya, S Glynos, T Dalal, D Branford, S Lipton, J H |
| author_sort | Hughes, T P |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5668492 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56684922017-11-07 Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results Hughes, T P Leber, B Cervantes, F Spector, N Pasquini, R Clementino, N C D Schwarer, A P Dorlhiac-Llacer, P E Mahon, F-X Rea, D Guerci-Bresler, A Kamel-Reid, S Bendit, I Acharya, S Glynos, T Dalal, D Branford, S Lipton, J H Leukemia Letter to the Editor Nature Publishing Group 2017-11 2017-09-01 /pmc/articles/PMC5668492/ /pubmed/28862704 http://dx.doi.org/10.1038/leu.2017.247 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Hughes, T P Leber, B Cervantes, F Spector, N Pasquini, R Clementino, N C D Schwarer, A P Dorlhiac-Llacer, P E Mahon, F-X Rea, D Guerci-Bresler, A Kamel-Reid, S Bendit, I Acharya, S Glynos, T Dalal, D Branford, S Lipton, J H Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results |
| title | Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results |
| title_full | Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results |
| title_fullStr | Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results |
| title_full_unstemmed | Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results |
| title_short | Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results |
| title_sort | sustained deep molecular responses in patients switched to nilotinib due to persistent bcr-abl1 on imatinib: final enestcmr randomized trial results |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/ https://www.ncbi.nlm.nih.gov/pubmed/28862704 http://dx.doi.org/10.1038/leu.2017.247 |
| work_keys_str_mv | AT hughestp sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT leberb sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT cervantesf sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT spectorn sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT pasquinir sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT clementinoncd sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT schwarerap sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT dorlhiacllacerpe sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT mahonfx sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT read sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT guercibreslera sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT kamelreids sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT benditi sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT acharyas sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT glynost sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT dalald sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT branfords sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults AT liptonjh sustaineddeepmolecularresponsesinpatientsswitchedtonilotinibduetopersistentbcrabl1onimatinibfinalenestcmrrandomizedtrialresults |